Have a personal or library account? Click to login

Liquisolid systems and aspects influencing their research and development

Acta Pharmaceutica
Volume 63 (2013): Issue 4 (December 2013)
By:
Open Access
|Dec 2013

References

  1. 1. M. Yazdanian, K. Briggs, C. Jankovsky and A. Hawi, The »high solubility« definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs, Pharm. Res. 21 (2004) 293-299; DOI: 10.1023/B:PHAM.0000016242.48642.71.10.1023/B:PHAM.0000016242.48642.71
    Search in Google Scholar
  2. 2. L. X. Yu, G. L. Amidon, J. E. Polli, H. Zhao, M. U. Mehta, D. P. Conner, V. P. Shah, L. J. Lesko, M. Chen, V. H. L. Lee and A. S. Hussain, Biopharmaceutics classification system: The scientific basis for biowaiver extensions, Pharm. Res. 19 (2002) 921-925; DOI: 10.1023/A:1016473601633.10.1023/A:1016473601633
    Search in Google Scholar
  3. 3. A. V. Yadav, A. S. Shete and A. P. Dabke, Formulation and evaluation of orodispersible liquisolid compacts of aceclofenac, Ind. J. Pharm. Educ. 44 (2010) 227-235.
    Search in Google Scholar
  4. 4. Y. Javadzadeh, M. R. Siahi, S. Asnaashari and A. Nokhodchi, Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties, Acta Pharm. 57 (2007) 99-109; DOI: 10.2478/v10007-007-0008-6.10.2478/v10007-007-0008-6
    Search in Google Scholar
  5. 5. S. Nazzal and M. A. Khan, Controlled release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parameters, Int. J. Pharm. 315 (2006) 110-121; DOI: 10.1016/j.ijpharm.2006.02.019.10.1016/j.ijpharm.2006.02.019
    Search in Google Scholar
  6. 6. N. Rasenack and B. W. Müller, Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs, Pharm. Res. 19 (2002) 1894-1900; DOI: 10.1023/A:1021410028371.10.1023/A:1021410028371
    Search in Google Scholar
  7. 7. A. B. Nighute and S. B. Bhise, Enhancement of dissolution rate of Rifabutin by preparation of microcrystals using solvent change method, Int. J. Pharm. Tech. Res. 1 (2009) 142-148.
    Search in Google Scholar
  8. 8. G. V. Betager and K. R. Makarla, Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques, Int. J. Pharm. 126 (1995) 155-160; DOI: 10.1016/0378-5173(95) 04114-1.
    Search in Google Scholar
  9. 9. J. W. Millard, F. A. Alvarez-Núñez and S. H. Yalkowsky Solubilization by cosolvents establishing useful constants for the log-linear model, Int. J. Pharm. 245 (2002) 153-166; DOI: 10.1016/ S0378-5173(02)00334-4.10.1016/S0378-5173(02)00334-4
    Search in Google Scholar
  10. 10. P. Balakrishnan, B. Le, D. H. Oh, J. O. Kim, M. J. Hong, J. Jee, J. A. Kim, B. K. Yoo, J. S. Woo, C. S. Yong and H. Choi, Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS), Eur. J. Pharm. Biopharm. 72 (2009) 539-545; DOI: 10.1016/j. ejpb.2009.03.001.
    Search in Google Scholar
  11. 11. A. Zvonar, K. Berginc, A. Kristl and M. Ga{perlin, Microencapsulation of self-microemulsifying system: Improving solubility and permeability of furosemide, Int. J. Pharm. 388 (2010) 151-158; DOI: 10.1016/j.ijpharm.2009.12.055.10.1016/j.ijpharm.2009.12.055
    Search in Google Scholar
  12. 12. H. A. Hassan, A. H. Al-Marzouqi, B. Jobe, A. A. Hamza and G. A. Ramadan, Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with b-cyclodextrin using supercritical carbon dioxide, J. Pharmaceut. Biomed. 45 (2007) 243-250; DOI: 10.1016/j.jpba.2007.06.011.10.1016/j.jpba.2007.06.011
    Search in Google Scholar
  13. 13. T. Tanino, T. Ogiso, M. Iwaki, G. Tanabe and O. Muraoka, Enhancement of oral bioavailability of phenytoin by esterification, and in vitro hydrolytic characteristics of prodrugs, Int. J. Pharm. 163 (1998) 91-102; DOI: 10.1016/S0378-5173(97)00374-8.10.1016/S0378-5173(97)00374-8
    Search in Google Scholar
  14. 14. S. G. Kapsi and J. W. Ayres, Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability, Int. J. Pharm. 229(2001) 193-203; DOI: 10.1016/S0378-5173(01)00867-5.10.1016/S0378-5173(01)00867-5
    Search in Google Scholar
  15. 15. D. X. Li, Y. Oh, S. Lim, J. O. Kim, H. J. Yang, J. H. Sung, C. S. Yong and H. Choi, Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique, Int.J. Pharm. 355 (2008) 277-284; DOI: 10.1016/j.ijpharm.2007.12.020.10.1016/j.ijpharm.2007.12.020
    Search in Google Scholar
  16. 16. V. Stella, J. Haslam, N. Yata, H. Okada, S. Lindenbaum and T. Higuchi, Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule, J. Pharm. Sci. 67 (1978) 1375-1377.10.1002/jps.2600671011
    Search in Google Scholar
  17. 17. V. K. Nagabandi, T. Ramarao and K. N. Jayaveera, Liquisolid compacts: A novel approach to enhance bioavailability of poorly soluble drugs, Int. J. Pharm. Biol. Sci. 1 (2011) 89-102.
    Search in Google Scholar
  18. 18. N. Tiong and A. A. Elkordy, Effects of liquisolid formulations on dissolution of naproxen, Eur. J. Pharm. Biopharm. 73 (2009) 373-384; DOI: 10.1016/j.ejpb.2009.08.002.10.1016/j.ejpb.2009.08.002
    Search in Google Scholar
  19. 19. K. Kavitha, K. N. S. LovaRaju, N. S. Ganesh and B. Ramesh, Effect of dissolution rate by liquisolid compacts approach: An overview, Der Pharmacia Lettre 3 (2011) 71-83.
    Search in Google Scholar
  20. 20. A. S. Kulkarni, N. H. Aloorkar, M. S. Mane and J. B. Gaja, Liquisolid systems: a review, Int. J. Pharm. Sci. Nanotechnol. 3 (2010) 795-802.
    Search in Google Scholar
  21. 21. S. M. Gavali, S. S. Pacharane, S. V. Sankpal, K. R. Jadhav and V. J. Kadam, Liquisolid compact: A new technique for enhancement of drug dissolution, Int. J. Res. Pharm. Chem. 1 (2011) 705-713.
    Search in Google Scholar
  22. 22. A. B. Karmarkar, I. D. Gonjari, A. H. Hosmani, P. N. Dhabale and S. B. Bhise, Liquisolid tablets: A novel approach for drug delivery, Int. J. Health Res. 2 (2009) 45-50.
    Search in Google Scholar
  23. 23. A. B. Karmarkar, I. D. Gonjari and A. H. Hosmani, Liquisolid technology for dissolution rate enhancement or sustained release, Expert Opin. Drug Deliv. 7 (2010) 1227-1234; DOI: 10.1517/17425247.2010.511173.10.1517/17425247.2010.511173
    Search in Google Scholar
  24. 24. M. El-Hammadi and N. Awad, Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on loratadine release, AAPSPharmSciTech. 13 (2012) 53-58; DOI: 10.1208/s12249-011-9719-6.10.1208/s12249-011-9719-6
    Search in Google Scholar
  25. 25. A. K. Elkhodairy and M. W. Samy, Optimization and evaluation of micromeritic and release properties of high dose flutamide liquisolid systems, Lett. Drug Des. Discov. 9 (2012) 336-344; DOI: 10.2174/157018012799129873.10.2174/157018012799129873
    Search in Google Scholar
  26. 26. Y. Javadzadeh, B. Jafari-Navimipour and A. Nokhodchi, Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine), Int. J. Pharm. 341 (2007) 26-34; DOI: 10.1016/j.ijpharm.2007.03.034.10.1016/j.ijpharm.2007.03.034
    Search in Google Scholar
  27. 27. S. K. Singh, K. K. Srinivasan, K. Gowthamarajan, D. Prakash, N. B. Gaikwad and D. S. Singare, Influence of formulation parameters on dissolution rate enhancement of glyburide using liquisolid technique, Drug Dev. Ind. Pharm. 38 (2012) 961-970; DOI: 10.3109/03639045.2011.634810.10.3109/03639045.2011.634810
    Search in Google Scholar
  28. 28. C. M. Hentzschel, A. Sakmann and C. S. Leopold, Suitability of various excipients as carrier and coating materials for liquisolid compacts, Drug Dev. Ind. Pharm. 37 (2011) 1200-1207; DOI: 10.3109/03639045.2011.564184.10.3109/03639045.2011.564184
    Search in Google Scholar
  29. 29. B. M. El-Houssieny, L. F. Wahman and N. M. Arafa, Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits, Biosci.Trends. 4 (2010) 17-24.
    Search in Google Scholar
  30. 30. K. A. Khaled, Y. A. Asiri and Y. M. El-Sayed, In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs, Int. J. Pharm. 222 (2001) 1-6; DOI: 10.1016/S0378-5173(01)00633-0.10.1016/S0378-5173(01)00633-0
    Search in Google Scholar
  31. 31. B. Chen, Z. Wang, G. Quan, X. Peng, X. Pan, R. Wang, Y. XU, G. Li and C. Wu, In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation, Int. J. Nanomed. 7 (2012) 199-209; DOI: 10.2147/IJN.S26763.10.2147/IJN.S26763
    Search in Google Scholar
  32. 32. R. H. Fahmy and M. A. Kassem, Enhancement of famotidine dissolution rate through liquisolid tablets formulation: In vitro and in vivo evaluation, Eur. J. Pharm. Biopharm. 69(2008) 993-1003; DOI: 10.1016/j.ejpb.2008.02.017.10.1016/j.ejpb.2008.02.017
    Search in Google Scholar
  33. 33. I. D. Gonjari, A. B. Karmarkar and A. H. Hosmani, Evaluation of in vitro dissolution profile comparison methods of sustained release tramadol hydrochloride liquisolid compact formulations with marketed sustained release tablets, Dig. J. Nanomater. Bios. 4 (2009) 651-661.
    Search in Google Scholar
  34. 34. H. S. Mahajan, M. R. Dhamne, S. G. Gattani, A. D. Rasal and H. T. Shaikh, Enhanced dissolution rate of glipizide by a liquisolid technique, Int. J. Pharm. Sci. Nanotech. 3 (2011) 1205-1213.
    Search in Google Scholar
  35. 35. Y. Javadzadeh, L. Musaalrezaei and A. Nokhodchi, Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices, Int. J. Pharm. 362 (2008) 102-108; DOI: 10.1016/j.ijpharm.2008.06.022. 10.1016/j.ijpharm.2008.06.022
    Search in Google Scholar
  36. 36. A. Nokhodchi, R. Aliakbar, S. Desai and Y. Javadzadeh, Liquisolid compacts: The effect of cosolvent and HPMC in theophylline release, Colloid Surface B. 79 (2010) 262-269; DOI: 10.1016/j. colsurfb.2010.04.008.
    Search in Google Scholar
  37. 37. Center for the Evaluation of Risks to Human Reproduction, NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of propylene glycol, Reprod. Toxicol. 18 (2004) 533-579; DOI: 10.1016/j.reprotox.2004.01.004.10.1016/j.reprotox.2004.01.004
    Search in Google Scholar
  38. 38. Cefic, Propylene Glycol - Pharmaceuticals, n.d.; http://www.propylene-glycol.com/index.php/propylene-glycol-ups-ep-pharmaceutical-grade/pharmaceuticals, access date January 17, 2012.
    Search in Google Scholar
  39. 39. S. Gubbi and R. Jarag, Liquisolid Technique for enhancement of dissolution properties of bromhexine hydrochloride, Res. J. Pharm. Tech. 2 (2009) 382-386.
    Search in Google Scholar
  40. 40. BASF group, Lutrol® E Liquid Grades, 2010; http://www.pharma-ingredients.basf.com/Statements/Technical%20Informations/EN/Pharma%20Solutions/03_030734e_Lutrol%20E%20-%20Liquid%20Grades.pdf; access date January 18, 2012.
    Search in Google Scholar
  41. 41. R. C. Rowe, P. J. Sheskey and S. C. Owen, Handbook of Pharmaceutical Excipients, 5th ed., Pharmaceutical Press, London 2006, p. 918.
    Search in Google Scholar
  42. 42. C. F. Daher, G. M. Baroody and R. J. Howland, Effect of a surfactant, Tween 80, on the formation and secretion of chylomicrons in the rat, Food Chem. Toxicol. 41 (2003) 575-582; DOI: 10.1016/ S0278-6915(02)00299-5.10.1016/S0278-6915(02)00299-5
    Search in Google Scholar
  43. 43. T. Tatsuishi, Y. Oyama, K. Iwase, J. Y. Yamaguchi, M. Kobayashi, Y. Nishimura, A. Kanada and S. Hirama, Polysorbate 80 increases the susceptibility to oxidative stress in rat thymocytes, Toxicology 207 (2005) 7-14; DOI: 10.1016/j.tox.2004.07.020.10.1016/j.tox.2004.07.02015590117
    Search in Google Scholar
  44. 44. W. Wang, Y. J. Wang and D. Q. Wang, Dual effect of Tween 80 on protein stability, Int. J. Pharm. 347 (2008) 31-38; DOI: 10.1016/j.ijpharm.2007.06.042.10.1016/j.ijpharm.2007.06.04217692480
    Search in Google Scholar
  45. 45. S. A. Tayel, I. I. Soliman and D. Louis, Improvement of dissolution properties of carbamazepine through application of the liquisolid tablet technique, Eur. J. Pharm. Biopharm. 69 (2008) 342-347; DOI: 10.1016/j.ejpb.2007.09.003.10.1016/j.ejpb.2007.09.00317949959
    Search in Google Scholar
  46. 46. M. Saeedi, J. Akbari, K. Morteza-Semnani, R. Enayati-Fard, S.Sar-Reshteh-dar and A. Soleymani, Enhancement of dissolution rate of indomethacin using liquisolid compacts, Iran J. Pharm.Res. 10 (2011) 25-34.
    Search in Google Scholar
  47. 47. V. B. Yadav and A. V. Yadav, Improvement of solubility and dissolution of indomethacin by liquisolid and compaction granulation technique, J. Pharm. Sci. Res. 1 (2009) 44-51.
    Search in Google Scholar
  48. 48. Y. Javadzadeh, M. R. Siahi-Shadbad, M. Barzegar-Jalali and A. Nokhodchi, Enhancement of dissolution rate of piroxicam using liquisolid compacts, Il Farmaco 60 (2005) 361-365; DOI: 10. 1016/j.farmac.2004.09.005.10.1016/j.farmac.2004.09.00515848213
    Search in Google Scholar
  49. 49. A. A. Elkordy, U. Bhangale, N. Murle and M. F. Zarara, Combination of lactose (as a carrier) with Cremophor® EL (as a liquid vehicle) to enhance dissolution of griseofulvin, Powder Technol. 246 (2013) 182-186; DOI: 10.1016/j.powtec.2013.05.024.10.1016/j.powtec.2013.05.024
    Search in Google Scholar
  50. 50. B. Akinlade, A. A. Elkordy, E. A. Essa and S. Elhagar, Liquisolid systems to improve the dissolution of furosemide, Sci. Pharm. 78 (2010) 325-344; DOI: 10.3797/scipharm.0912-23.10.3797/scipharm.0912-23
    Search in Google Scholar
  51. 51. C. C. Liao and C. I. Jarowski, Dissolution rates of corticoid solutions dispersed on silicas, J. Pharm.Sci. 73 (1984) 401-403; DOI: 10.1002/jps.2600730330.10.1002/jps.2600730330
    Search in Google Scholar
  52. 52. A. A. Elkordy, X. N. Tan and E. A. Essa, Spironolactone release from liquisolid formulations prepared with CapryolTM 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles, Eur. J. Pharm. Biopharm. 83 (2013) 203-223; DOI: 10.1016/j.ejpb.2012.08.004.10.1016/j.ejpb.2012.08.004
    Search in Google Scholar
  53. 53. A. A. Elkordy, E. A. Essa, S. Dhuppad and P. Jammiqumpula, Liquisolid technique to enhance and to sustain griseofulvin dissolution: effect of choice of non-volatile liquid vehicles, Int. J. Pharm. 434 (2012) 122-132; DOI: 10.1016/j.ijpharm.2012.05.072. 10.1016/j.ijpharm.2012.05.072
    Search in Google Scholar
  54. 54. V. Agarwal, A. Siddiqui, H. Ali and S. Nazzal, Dissolution and power flow characterization of solid self-emulsified drug delivery system (SEDDS), Int. J. Pharm. 366 (2009) 44-52; DOI: 10. 1016/j.ijpharm.2008.08.046.10.1016/j.ijpharm.2008.08.046
    Search in Google Scholar
  55. 55. G. Kahr and F. T. Madsen, Determination of the cation exchange capacity and the surface area of bentonite, illite and kaolinite by methylene blue absorption, Appl. Clay Sci. 9 (1995) 327-336; DOI: 10.1016/0169-1317(94)00028-O.10.1016/0169-1317(94)00028-O
    Search in Google Scholar
  56. 56. M. Van Speybroeck, R. Mellaerts, R. Mols, T. D. Thi, J. A. Martens, J. Van Humbeeck, P. Annaert, G. Van den Mooter and P. Augistijns, Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica, Eur. J. Pharm. Sci. 41 (2010) 623-630; DOI: 10.1016/j.ejps.2010.09.002.10.1016/j.ejps.2010.09.00220850527
    Search in Google Scholar
  57. 57. V. B. Yadav, A. B. Nighute, A. V. Yadav and S. B. Bhise, Aceclofenac size enlargement by non- -aqueous granulation with improved solubility and dissolution, Arch. Pharm. Sci. Res. 1 (2009) 115-122.
    Search in Google Scholar
  58. 58. P. G. Manogar, B. N. V. Hari and D. R. Devi, Emerging liquisolid compact technology for solubility enhancement of BCS Class-II drug, J. Pharm. Sci. Res. 3 (2011) 1604-1611.
    Search in Google Scholar
  59. 59. Fuji Chemical Industry Co., Ltd., Neusilin - Generel Properties, 2010; http://www.neusilin.com/product/general_properties.php; access date October 18, 2012.
    Search in Google Scholar
  60. 60. C. M. Hentzschel, M. Alnaief, I. Smirnova, A. Sakmann and C. S. Leopold, Tableting properties of silica aerogels and other silicates, Drug Dev. Ind. Pharm. 38 (2012) 462-467; DOI: 10.3109/03639045.2011.611806.10.3109/03639045.2011.61180621961994
    Search in Google Scholar
  61. 61. Fuji Chemical Industry Co., Ltd., Neusilin, 2011; http://www.fujichemical.co.jp/english/medical/ medicine/neusilin/index.html; access date October 18, 2012.
    Search in Google Scholar
  62. 62. Fuji Chemical Industry Co., Ltd., The Specialty Excipient Neusilin®, 2009; http://www.harke. com/fileadmin/images/pharma/Broschueren/Fuji_Neusilin.pdf; access date January 18, 2012.
    Search in Google Scholar
  63. 63. X. Zhao, Y. Q. Zhou, S. Potharaju, H. Lou, H. M. Sun, E. Brunson, H. Almoazen and J. Johnson, Development of a self micro-emulsifying tablet of cyclosporine-A by the liquisolid compact technique, Int. J. Pharm. Sci. Res. 2 (2011) 2299-2308.
    Search in Google Scholar
  64. 64. B. Van Eerdenbrugh, L. Froyen, J. Van Humbeeck, J. A. Martens, P. Augustijns and G. Van Den Mooter, Alternative matrix formers for nanosupension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion, Eur. J. Pharm. Sci. 35 (2008) 344-353; DOI: 10.1016/j.ejps.2008.08.003.10.1016/j.ejps.2008.08.00318765282
    Search in Google Scholar
  65. 65. M. J. Kang, S. Y. Jung, W. H. Song, J. S. Park, S. U. Choi, K. T. Oh, H. K. Choi, Y. W. Choi, J. Lee, B. J. Lee and S. C. Chi, Immediate release of ibuprofen from Fujicalin®-based fast-dissolving self-emulsifying tablets, Drug Dev. Ind. Pharm. 37 (2011) 1298-1305; DOI:10.3109/03639045.2011.571695.10.3109/03639045.2011.57169521476949
    Search in Google Scholar
  66. 66. H. Schlack, A. Bauer-Brandl, R. Schubert and D. Becker, Properties of Fujicalin®, A new modified anhydrous dibasic calcium phosphate for direct compression: Comparison with dicalcium phosphate dihydrate, Drug Dev. Ind. Pharm. 27 (2001) 789-801.10.1081/DDC-100107242
    Search in Google Scholar
  67. 67. Z. Wu, Y. Jiang, T. Kim and K. Lee, Effect of surface coating on the controlled release of vitamin B1 from mesoporous silica tablets, J. Control. Release 119 (2007) 215-221; DOI: 10.1016/j.jconrel. 2007.03.001.
    Search in Google Scholar
  68. 68. T. Ukmar and O. Planin{ek, Ordered mesoporous silicates as matrices for controlled release of drugs, Acta Pharm. 60 (2010) 373-385; DOI: 10.2478/v1007-010-0037-4.10.2478/v1007-010-0037-421169131
    Search in Google Scholar
  69. 69. M. Vallet-Regi, A. Ramila, R. P. del Rea and J. Pérez-Pariente, A new property of MCM-41: drug delivery system, Chem. Mater. 13 (2001) 308-311; DOI: 10.1021/cm0011559.70. R. Mellaerts, R. Mois, J. A. G. Jammaer, C. A. Aerts, P. Annaert, J. Van Humbeeck, G. Van den Mooter, P. Augustijns and J. A. Martens, Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica, Eur. J. Pharm. Biopharm. 69 (2008) 223-230; DOI: 10.1016/j.ejpb.2007.11.006. 10.1016/j.ejpb.2007.11.00618164930
    Search in Google Scholar
  70. 71. M. Vialpando, F. Backhuijs, J. A. Martens and G. Van den Mooter, Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds intraconazole, fenofibrate, naproxen, and ibuprofen, Eur. J. Pharm. Biopharm. 81 (2012) 190-198; DOI: 10.1016/j.ejpb.2012.01.012.10.1016/j.ejpb.2012.01.01222306694
    Search in Google Scholar
  71. 72. T. Heikkilä, J. Salonen, J. Tuura, N. Kumar, T. Salmi, D. Y. Murzin, M. S. Hamdy, G. Mul, L. Laitinen, A. M. Kaukonen, J. Hirvonen and V. P. Lehto, Evaluation of mesoporous TCPSi, MCM-41, SBA-15 and TUD-1 materials as API carriers for oral drug delivery, Drug Deliv. 14 (2007) 337-347; DOI: 10.1080/10717540601098823.10.1080/1071754060109882317701523
    Search in Google Scholar
  72. 73. M. Van Speybroeck, V. Barillaro, T. D. Thi, R. Mellaerts, J. Martens, J. Van Humbeeck, J. Vermant, P. Annaert, G. Van den Mooter and P. Augustijns, Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs, J. Pharm. Sci. 98 (2009) 2648-2658; DOI: 10.1002/jps.21638.10.1002/jps.2163819072861
    Search in Google Scholar
  73. 74. B. Chen, G. Quan, Z. Wang, J. Chen, L. Wu, Y. Xu, G. Li and C. Wu, Hollow mesoporoussilicas as a drug solution delivery system for insoluble drugs, Powder Technol. 240 (2013) 48-53; DOI: 10.1016/j.powtec.2012.07.008.10.1016/j.powtec.2012.07.008
    Search in Google Scholar
  74. 75. S. R. Gubbi and R. Jarag, Formulation and characterization of atorvastatin calcium liquisolid compacts, Asian J. Pharm. Sci. 5 (2010) 50-60.
    Search in Google Scholar
  75. 76. K. M. El-Say, A. M. Samy and M. I. Fetouh, Formulation and evaluation of rofecoxib liquisolid tablets, Int. J. Pharm. Sci. Rev. Res. 3 (2010) 135-142.
    Search in Google Scholar
  76. 77. A. Krupa, D. Majda, R. Jachowicz and W. Mozgawa, Solid-state interaction of ibuprofen and Neusilin US2, Thermochim. Acta 509 (2010) 12-17; DOI: 10.1016/j.tca.2010.05.009.10.1016/j.tca.2010.05.009
    Search in Google Scholar
  77. 78. A. Sheth and C. I. Jarowski, Use of powdered solutions to improve the dissolution rate of polythiazide tablets, Drug Dev. Ind. Pharm. 16 (1990) 769-777; DOI: 10.3109/03639049009114908.10.3109/03639049009114908
    Search in Google Scholar
  78. 79. E. B. Basalious, W. El-Sebaie and O. El-Gazayerly, Rapidly absorbed orodispersible tablet containing molecularly dispersed felodipine for management of hypertensive crisis: Development, optimization and in vitro/in vivo studies, Pharm. Dev. Technol. 18 (2013) 407-416; DOI: 10.3109/
    Search in Google Scholar
  79. 10837450.2012.659258.
    Search in Google Scholar
  80. 80. S. S. Spireas, C. I. Jarowski and B. D. Rohera, Powdered solution technology: Principles and mechanism, Pharm. Res. 9 (1992) 1351-1358; DOI: 10.1023/A:1015877905988.10.1023/A:1015877905988
    Search in Google Scholar
  81. 81. M. Khanfar, S. M. Sheikh and R. Hawari, Formulation factors affecting the release of ezetimibe from different liquisolid compacts, Pharm. Dev. Technol. 18 (2013) 417-427; DOI: 10.3109/10837450.2012.680594.10.3109/10837450.2012.680594
    Search in Google Scholar
  82. 82. S. Spireas and S. M. Bolton, Liquisolid Systems and Methods of Preparing Same, US 5,968,550, 19 October 1999.
    Search in Google Scholar
  83. 83. S. Spireas and S. M. Bolton SM, Liquisolid Systems and Methods of Preparing Same, US 6,423,339, 23 July 2002.
    Search in Google Scholar
  84. 84. K. Rajesh, R. Rajalakshmi, J. Umamaheswari and C. K. A. Kumar, Liquisolid technique: a novel approach to enhance solubility and bioavailability, Int. J. Biopharm. 2 (2011) 8-13.
    Search in Google Scholar
  85. 85. R.Grover, S. Spireas and C. Lau-Cam, Development of a simple spectrophotometric method for propylene glycol detection in tablets, J. Pharm. Biomed. Anal. 16 (1998) 931-938; DOI: 10.1016/ S0731-7085(97)00098-8.10.1016/S0731-7085(97)00098-8
    Search in Google Scholar
  86. 86. R. Boghra, A. Patel, H. Desai and A. Jadhav, Formulation and evaluation of irbesartan liquisolid tablets, Int. J. Pharm. Sci. Rev. Res. 9 (2011) 32-37.
    Search in Google Scholar
  87. 87. S. V. Kasture, S. B. Gondkar, A. B. Darekar, D. Priyobrata and K. V. Bhambar, Enhancement of dissolution rate of lansoprazole using liquisolid tablet technique, Int. J. Pharm. Res. 3 (2011) 27-31.
    Search in Google Scholar
  88. 88. M. A. Hassan and H. M. El-Saghir, Enhancement of dissolution and the anti-inflammatory effect of nimesulide, using liquisolid compact for oral appliccation, Bull. Pharm. Sci. 34 (2011) 1-8. 10.1248/bpb.34.1
    Search in Google Scholar
  89. 89. The European Directorate for the Quality of Medicines & Health Care, European Pharmacopoeia 7.2, 2011; http://online6.edqm.eu/ep702/; access date February 18, 2012.
    Search in Google Scholar
  90. 90. D. C. Bibby, N. M. Davies and I. G. Tucker, Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems, Int. J. Pharm. 197 (2000) 1-11; DOI: 10.1016/S0378-5173(00)00335-5.10.1016/S0378-5173(00)00335-5
    Search in Google Scholar
  91. 91. D. Q. Craig, The mechanisms of drug release from solid dispersions in water-soluble polymers, Int. J. Pharm. 231 (2002) 131-144; DOI: 10.1016/S0378-5173(01)00891-2.10.1016/S0378-5173(01)00891-2
    Search in Google Scholar
  92. 92. A. Nokhodchi, C. M. Hentzschel and C. S. Leopold, Drug release from liquisolid systems: speed it up, slow it down, Expert Opin. Drug Deliv. 8 (2011) 191-205; DOI: 10.1517/17425247.2011.548801.10.1517/17425247.2011.54880121222556
    Search in Google Scholar
  93. 93. A. Panda and D. M. Biyani, Studies on liquisolid system as a technique to modify the dissolution rate of nefedipine, Am. J. Pharmtech. Res. 3 (2013) 686-698.
    Search in Google Scholar
  94. 94. N. Chella, N. Shastri and R. R. Tadikonda, Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan, Acta Pharm. Sin B. 2 (2012) 502-508; DOI: 10.1016/j. apsb.2012.07.005..
    Search in Google Scholar
  95. 95. N. Thakur, S. L. Khokra, D. Sharma, N. S. Thakur, R. Purohit and V. Arya, A review on pharmaceutical application of liquisolid technique, Am. J. Pharmtech. Res. 1 (2011) 1-18.
    Search in Google Scholar
DOI: https://doi.org/10.2478/acph-2013-0034 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 447 - 465
Published on: Dec 31, 2013
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
bioavailability improvement,
carrier material,
enhanced release,
liquid drug,
liquisolid technology
Related subjects:
Pharmacy,
Pharmacy, other

© 2013 Barbora Vraníková, Jan Gajdziok, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.

Previous articleVolume 63 (2013): Issue 4 (December 2013)Next article